07:15 AM EDT, 10/08/2024 (MT Newswires) -- SAGE Therapeutics ( SAGE ) said Tuesday that topline results from its phase 2 LIGHTWAVE study for the treatment of mild cognitive impairment or mild dementia due to Alzheimer's disease did not demonstrate a statistically significant difference in dalzanemdor-treated participants versus placebo.

As a result, the company said it does not plan further clinical development of dalzanemdor in Alzheimer's disease.

The company expects to report topline data from the phase 2 DIMENSION study of dalzanemdor in people with cognitive impairment associated with Huntington's Disease later this year.

Sage's share price dropped more than 12% in recent premarket activity on Tuesday.

Price: 5.90, Change: -0.82, Percent Change: -12.20